Results 11 to 20 of about 15,991 (171)
Medical Journal Armed Forces India, 2009 Recombinant activated factor VII (rFVIIa) was originally developed for the treatment of hemophilic patients with inhibitors and then used successfully for treating hemorrhages in patients with acquired hemophilia. In the last few years, along with the improvement in the knowledge of its mechanisms of action, rFVIIa has also been used with benefit as a “
P, Kinra, H, Kumar
openaire +2 more sources
Inhibitors of Factor VIIa/Tissue Factor [PDF]
Arteriosclerosis, Thrombosis, and Vascular Biology, 2007 The formation of the proteolytic complex composed of the serine protease Factor VIIa and the cell-associated glycoprotein tissue factor (FVIIa/TF) initiates a cascade of amplified zymogen activation reactions leading to thrombus formation. The critical role of the coagulation cascade in pathological thrombosis has been the basis for significant efforts
Rebecca A, Shirk, George P, Vlasuk
openaire +2 more sources
FVIIa (Factor VIIa) Induces Biased Cytoprotective Signaling in Mice Through the Cleavage of PAR (Protease-Activated Receptor)-1 at Canonical Arg41 (Arginine41) Site [PDF]
Arteriosclerosis, Thrombosis, and Vascular Biology, 2020 Vijay Kondreddy +2 more
exaly +2 more sources
Haematologica, 2015 Standard treatment for Glanzmann thrombasthenia, a severe inherited bleeding disorder, is platelet transfusion. Recombinant factor VIIa is reported to be effective in Glanzmann thrombasthenia with platelet antibodies and/or refractoriness to platelet ...
Man-Chiu Poon +5 more
doaj +1 more source
Clinics and Practice, 2015 Symptomatic intracerebral hemorrhage (sICH) occurs in up to 7% of stroke patients treated with thrombolytic therapy. There are limited data on the effectiveness of the reversal agents used for intravenous tissue plasminogen activator related intracranial
Shadi Yaghi +4 more
doaj +1 more source
Journal of the Formosan Medical Association, 2006 Recombinant factor VIIa (rFVIIa) was developed for the treatment of bleeding in hemophilic patients with inhibitors. It has also been used to stop bleeding in nonhemophilic patients who fail to respond to conventional treatment.
Yu-Feng Wei +4 more
doaj +1 more source
Haematologica, 2008 Background A soluble form of endothelial cell protein C receptor (sEPCR) is generated by shedding of the cellular form. sEPCR binds to protein C and factor VIIa and inhibits both the activation of protein C and the activity of activated protein C and ...
Eva Molina +4 more
doaj +1 more source
The prophylactic use of recombinant factor VIIa in a patient with DeBakey type III aortic dissection -A case report- [PDF]
Korean Journal of Anesthesiology, 2011 Little is known about the prophylactic use of recombinant factor VIIa (rFVIIa) in patients undergoing surgery for a bleeding aorta employing cardiopulmonary bypass.
Wook Jong Kim +7 more
doaj +1 more source
Combination of novoseven and feiba in hemophiliac patients with inhibitors
Open Medicine, 2018 The aim of this study is to investigate the effective therapeutic combination of recombinant VIIa(Novoseven) and factor eight inhibitor bypass activity(FEIBA) drugs for the bleedings of adult hemophiliac patients with inhibitors.19 bleeding episodes of 5
Malkan Umit Yavuz, Aksu Salih
doaj +1 more source
TH Open, 2019 Tissue factor (TF)-positive microvesicles from various sources can promote cellular proliferation or alternatively induce apoptosis, but the determining factors are unknown.
Yahya Madkhali +5 more
doaj +1 more source